Abbott Laboratories earns a Buy as medical devices and FreeStyle Libre power growth, while margin improvement and raised guidance support the case. Valuation is still premium, so the stock looks attractive but not cheap.
Abbott Laboratories (ABT) earns a Buy rating for a moderate-risk, medium-term portfolio. The investment case rests on a diversified healthcare platform, strong medical-device momentum, a large FreeStyle Libre continuous glucose monitoring franchise, and improving margins. In the second quarter of 2026, sales reached $12.59B, reported sales growth was 13.0%, comparable sales growth was 4.8%, and adjusted EPS was $1.31. Abbott also raised its 2026 adjusted EPS guidance to $5.45 to $5.60.
The growth engine is becoming more concentrated in higher-value businesses. Medical Devices represented 48.3% of 2025 segment revenue and grew 9.0% on a reported basis in the second quarter. Diabetes care, electrophysiology, rhythm management, and heart failure all supplied specific growth drivers. Diagnostics added cancer-screening momentum through Cologuard, while Established Pharmaceuticals produced 8.4% reported growth in the quarter.
The main restraint is valuation and earnings consistency. ABT trades at 33.1 times trailing earnings, compared with 17.1 times forward earnings, and its PEG ratio is 1.9. The company has beaten quarterly EPS estimates in 3 of the last 7 reported quarters, while TTM earnings growth was negative 47.5%. That combination supports a positive stance, but not an aggressive one. The stock price of $103.04 leaves room for execution, although the market already assigns a premium to Abbott's quality.
Abbott Laboratories was founded in 1888 and is headquartered in Abbott Park, Illinois. The company operates in four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Abbott sells through hospitals, laboratories, physicians' offices, retailers, wholesalers, government agencies, and distributors in more than 160 countries.
The portfolio spans branded generic pharmaceuticals, infant and adult nutrition, laboratory systems, rapid tests, cardiovascular devices, neuromodulation products, and glucose monitoring. This breadth gives Abbott several demand streams rather than a single product cycle. It also creates operational complexity, because each segment faces different reimbursement rules, regulatory processes, procurement channels, and competitive threats.
In 2025, Abbott generated $44.31B of segment revenue. Medical Devices contributed $21.39B, Diagnostics $8.94B, Nutrition $8.45B, and Established Pharmaceuticals $5.54B. Medical Devices increased its share of the portfolio from 45.3% in 2024 to 48.3% in 2025, while Diagnostics declined from 22.3% to 20.2% as respiratory testing normalized.
Medical Devices is Abbott's principal growth segment. Second-quarter reported sales were $5.85B, up 9.0%, with comparable growth of 8.4%. Electrophysiology benefited from the US launch of Bolt 2.0, while rhythm management sales grew 9.5% and heart failure sales grew 9%. Diabetes care sales exceeded $2.0B in the quarter and grew 9.5%.
Diagnostics produced $3.09B of second-quarter reported sales, up 42.3% because of acquisition and structural effects, while comparable growth was 2.9%. Core laboratory demand was stronger, with US core laboratory sales up 7.5% and hospital laboratory business up 13%. Rapid and molecular diagnostics declined 8% as respiratory testing demand weakened.
Nutrition generated $2.14B of second-quarter reported sales, down 3.1%, or 3.6% on a comparable basis. The segment is recovering sequentially, with sales up $125M from the prior quarter. International pediatric nutrition grew 6.5%, US pediatric nutrition benefited from WIC contract wins, and US retail consumption of Ensure increased at a double-digit rate from the end of 2025.
Established Pharmaceuticals generated $1.50B in second-quarter sales, up 8.4% reported and 8.7% comparable. Growth was broad across India, Latin America, and Southeast Asia. Abbott's 10-K identifies branded generics, biosimilars, women's health, gastroenterology, cardiovascular, metabolic, pain, and respiratory products as the segment's principal categories.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
FreeStyle Libre is Abbott's flagship growth product. Diabetes care generated $7.6B in 2025, up 17.4% excluding foreign exchange from 2024. Abbott's investor materials describe Libre as the world's most widely used biowearable, with more than 8 million users. The scale creates a recurring sensor-consumable model rather than a one-time equipment sale.
The second-quarter CGM result was substantial even after a slower growth period. Sales exceeded $2.0B and rose 9.5% year over year. Abbott secured the CE Mark for Libre Duo in May 2026. The device combines glucose and ketone monitoring, with international rollout planned for the fall and US commercialization tied to FDA approval.
That management comment frames the opportunity, but it also identifies the central dependency: reimbursement. Abbott said France, Japan, and Canada have broadly adopted CGM reimbursement and that discussions cover another seven significant markets. Management also cited a potential US expansion involving approximately 10 million Medicare beneficiaries. The opportunity is large, while the timing of reimbursement decisions remains a variable in the growth path.
Abbott's competitive advantage comes from installed bases, recurring consumables, clinical data, and regulatory know-how. Alinity laboratory systems, Libre sensors, cardiac mapping platforms, and implanted cardiovascular devices connect Abbott to repeat usage. Once a hospital laboratory or patient adopts a platform, replacement products, reagents, sensors, software, and service relationships support recurring revenue.
The near-term pipeline is unusually broad. Abbott completed enrollment in its tectonic coronary intravascular lithotripsy trial, submitted Amulet 360 for FDA approval, and secured the CE Mark for Libre Duo. The company also plans launches involving TactiFlex Duo, a balloon-expandable TAVR valve, a leadless conduction-system pacing device, a mitral replacement valve, a peripheral IVL device, and a wearable lactate sensor.
Research spending also supports the product cycle. Adjusted R&D was 6.9% of sales in the second quarter. Abbott's 10-K states that the company owns or licenses a substantial number of patents and patent applications, with material patents expiring between 2026 and 2046 in aggregate. The moat is therefore based on a portfolio of technologies and approvals, not a single patent.
Abbott purchases raw materials and supplies from numerous suppliers in the US and around the world. Its 10-K reported no recent significant availability problems for essential materials. The same filing describes a global manufacturing and distribution structure serving hospitals, laboratories, retailers, government agencies, and consumers.
Capacity planning is becoming most important in CGM. Management said Abbott's fourth sensor facility has a capacity of 100 million sensors and that the company is planning a fifth facility. The proposed investment was described as approximately $1.0B, with the location decision still under review between the US and international sites.
Foreign exchange helped second-quarter sales by 0.8%. Abbott expects a 1% positive effect on full-year 2026 sales at current exchange rates, alongside an estimated 1% negative impact on third-quarter sales. That contrast shows how quickly currency can alter reported performance for a company with global operations.
Abbott participates in several large healthcare markets rather than one standardized market. One industry estimate places the global medical devices market at $810.4B in 2024 and $1.3T in 2029, implying a 9.8% CAGR. A separate durable medical equipment estimate places that market at $231.85B in 2025 and $319.54B in 2031, implying a 5.4% CAGR.
The most attractive growth pockets are connected monitoring, diabetes care, electrophysiology, structural heart, and home-based care. Home healthcare is projected to grow at a 9.9% CAGR through 2031 in one industry estimate, while online and direct-to-patient channels are projected to grow at 11.9%. Abbott's Libre platform and heart-failure monitoring products align with those channel shifts.
Hospitals still represent the core buying center. One US medical-device estimate assigns hospitals 65.5% of end-user demand in 2025 and projects ambulatory surgery centers to grow at a 7.7% CAGR. Abbott's portfolio reaches both sides of that market through hospital laboratory systems, cardiovascular devices, outpatient procedures, and home monitoring.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Abbott serves four distinct customer groups. Hospitals and laboratories buy diagnostic instruments, reagents, cardiovascular devices, and monitoring systems. Physicians and clinics use testing platforms and procedure-based devices. Retailers and consumers purchase nutrition products and glucose-monitoring supplies. Government agencies and distributors participate in pharmaceutical, nutrition, and diagnostic procurement.
Diagnostics gives Abbott a particularly broad view of healthcare utilization. Management stated that diagnostic test results inform approximately 70% of healthcare decisions. US testing volumes have held up well, and Abbott's hospital laboratory business grew 13% in the second quarter. Those figures support the durability of lab demand even as respiratory testing declines.
Customer concentration is limited at the corporate level. Abbott's 10-K states that no single customer would have a material adverse effect if lost. Within specific categories, reimbursement still matters. WIC contracts supported US pediatric nutrition, while Medicare accounts for more than two-thirds of Abbott's US cardiovascular business according to management.
Dexcom is Abbott's clearest direct competitor in CGM. Medtronic also competes in glucose monitoring and integrated insulin-delivery systems. Roche Diabetes Care, LifeScan, and Ascensia compete in blood glucose monitoring. The market is increasingly platform-based, combining sensors, pumps, software, data, and reimbursement rather than treating the sensor as an isolated product.
Diagnostics competitors include Roche, Siemens Healthineers, Danaher, Becton Dickinson, bioMérieux, QuidelOrtho, Thermo Fisher, and Werfen. Medical-device competitors include Medtronic, Boston Scientific, Johnson & Johnson MedTech, Edwards Lifesciences, Stryker, Terumo, and Becton Dickinson. Abbott's advantage is breadth across these categories, while its disadvantage is that it faces specialized leaders in nearly every product line.
Abbott's 2025 CGM sales of $7.6B and more than 8 million Libre users provide scale against focused competitors. Medical Devices also delivered 11.9% organic growth in 2025, led by Diabetes Care, Heart Failure, Electrophysiology, and Structural Heart. The competitive test is whether new products preserve that growth as rivals improve their own devices and software ecosystems.
Aging supports Abbott's long-term demand profile. Robert Ford stated that approximately 10,000 people in the US turn 65 each day and identified age as a major healthcare demand driver. Diabetes, cardiovascular disease, cancer screening, and chronic heart failure all connect directly to Abbott's product portfolio.
China remains a specific pressure point. Management described a volume-based procurement impact that reduced part of the China diagnostics business by approximately 30% for at least five quarters. Abbott still forecast a China decline in the second half, although management described the expected decline as mid-single digit. This is a pricing and volume issue rather than a broad collapse in global diagnostic demand.
Regulation and reimbursement shape the economics of every major segment. Abbott's 10-K identifies FDA and international approval, manufacturing controls, post-market surveillance, pricing, reimbursement, cybersecurity, and data privacy as material operating requirements. The company also faces reimbursement pressure from government and private payors, including competitive bidding for certain diabetes products.
Abbott’s balance sheet earns an A- thanks to a diversified business mix and enough financial flexibility to support continued investment across devices, diagnostics, nutrition, and pharmaceuticals.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Second-quarter sales reached $12.59B with 13.0% reported growth and adjusted EPS of $1.31, while 2026 guidance was lifted to $5.45-$5.60.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Abbott has beaten quarterly EPS estimates in 3 of the last 7 reported quarters, and TTM earnings growth was negative 47.5% even as analysts look for better execution ahead.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Abbott trades at 33.1x trailing earnings, 17.1x forward earnings, and a 1.9 PEG, leaving the shares priced for quality rather than a bargain.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Abbott’s price framework spans $88 to $135, with $110 marking the fair value that sits between a more cautious view and a premium-quality multiple.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Abbott is transitioning from a diversified healthcare conglomerate into a more device-led growth platform. Medical Devices now supplies nearly half of segment revenue, while Libre, electrophysiology, structural heart, heart failure, and cancer diagnostics provide identifiable expansion paths. The second quarter delivered stronger sales momentum, a 100-basis-point adjusted gross-margin improvement, and a raised EPS outlook.
The investment case is strongest when the purchase price respects the distinction between a high-quality business and a risk-free stock. Abbott has $7.39B of annual free cash flow, a 0.25 debt-to-equity ratio, and a $110 fair value estimate, but it also has a 33.1 times trailing P/E, an uneven recent beat record, China pricing pressure, and reimbursement-sensitive growth.
At $103.04, the risk-reward profile supports a Buy rather than a Strong Buy. Investors who prioritize durable healthcare demand, recurring device revenue, and a broad innovation pipeline have a credible medium-term case. The most disciplined approach is to build exposure near the Buy target and demand stronger execution before paying the Sell-level valuation.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Abbott Laboratories (ABT) climbs after posting stronger-than-expected second-quarter results and raising full-year profit guidance. The healthcare giant’s earnings beat, sales growth, and improved outlook are driving a sharp revaluation as investors reassess its earnings power and recovery potential.
Abbott is evolving from a defensive healthcare name into a stronger medtech-led compounder, helped by Medical Devices growth and the Exact Sciences deal. Nutrition remains a drag, but the stock looks attractive on weakness rather than at any price.